Adverum Biotechnologies Inc (ADVM NASDAQ) stock market data APIs
$2.1532
0.21(9.8%)
as of June 30, 2025
Try our APIs with
free plan!
Adverum Biotechnologies Inc Financial Data Overview
Price chart is built with
Anychart
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Prev. Close
2.1532
Open
2.3623
High
2.4328
Low
2.1125
52 wk Range
1.78-10.14
Market Cap
48 466 K
Shares Outstanding
20 891 K
Revenue
1 000 K
EPS
-1.9586
Beta
0.703
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adverum Biotechnologies Inc data using free add-ons & libraries
Get Adverum Biotechnologies Inc Fundamental Data
Adverum Biotechnologies Inc Fundamental data includes:
- Net Revenue: 1 000 K
- EBITDA: -154 842 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -1.974
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adverum Biotechnologies Inc News
New
Adverum Biotechnologies price target lowered to $12 at Mizuho
Investing.com - Mizuho lowered its price target on Adverum Biotechnologies (NASDAQ:ADVM) stock to $12.00 from $16.00 on Wednesday, while maintaining an Outperform rating on the shares. The stock, curr...
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a biotechnology company focused on developing gene therapies for ocular and rare diseases, stands at a critical juncture in its journey to bring innovative...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducem...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
